1. 033 Effect of ocrelizumab on upper limb function in patients with primary progressive multiple sclerosis (PPMS) in the oratorio study (ENCORE). Issue 6 (24th May 2018) Authors: Fox, Edward; Markowitz, Clyde; Applebee, Angela; Montalban, Xavier; Wolinsky, Jerry S; Belachew, Shebeshih; Fiore, Damian; Han, Jian; Musch, Bruno; Giovannoni, Gavin Journal: Journal of neurology, neurosurgery and psychiatry Issue: Volume 89:Issue 6(2018) Page Start: A14 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. An exploratory analysis of the efficacy of ocrelizumab in patients with multiple sclerosis with increased disability. Issue 1 (March 2020) Authors: Wolinsky, Jerry S; Engmann, Natalie J; Pei, Jinglan; Pradhan, Ashish; Markowitz, Clyde; Fox, Edward J Journal: Multiple sclerosis journal, experimental, translational and clinical Issue: Volume 6:Issue 1(2020) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Dirucotide (MBP8298) for the treatment of multiple sclerosis. Issue 5 (September 2008) Authors: Markowitz, Clyde Journal: Therapy Issue: Volume 5:Issue 5(2008) Page Start: 605 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Ocrelizumab reduces progression of upper extremity impairment in patients with primary progressive multiple sclerosis: Findings from the phase III randomized ORATORIO trial. (December 2018) Authors: Fox, Edward J; Markowitz, Clyde; Applebee, Angela; Montalban, Xavier; Wolinsky, Jerry S; Belachew, Shibeshih; Fiore, Damian; Pei, Jinglan; Musch, Bruno; Giovannoni, Gavin Journal: Multiple sclerosis Issue: Volume 24:Number 14(2018) Page Start: 1862 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗